Showing 1–8 of 8 results
-
Research |
Mutations driving CLL and their evolution in progression and relapse
- Stephan.Stilgenbauer@uniklinik-ulm.de
- Dan A. Landau
- , Eugen Tausch
- , Amaro N. Taylor-Weiner
- , Chip Stewart
- , Johannes G. Reiter
- , Jasmin Bahlo
- , Sandra Kluth
- , Ivana Bozic
- , Mike Lawrence
- , Sebastian Böttcher
- , Scott L. Carter
- , Kristian Cibulskis
- , Daniel Mertens
- , Carrie L. Sougnez
- , Mara Rosenberg
- , Julian M. Hess
- , Jennifer Edelmann
- , Sabrina Kless
- , Michael Kneba
- , Matthias Ritgen
- , Anna Fink
- , Kirsten Fischer
- , Stacey Gabriel
- , Eric S. Lander
- , Martin A. Nowak
- , Hartmut Döhner
- , Michael Hallek
- , Donna Neuberg
- , Gad Getz
- , Stephan Stilgenbauer
- & Catherine J. Wu
-
Research | | Open
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
- Stephan.Stilgenbauer@uniklinik-ulm.de
-
Research |
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia
- stephan.stilgenbauer@uniklinik-ulm.de
- Billy Michael Chelliah Jebaraj
- , Eugen Tausch
- , Dan A. Landau
- , Jasmin Bahlo
- , Sandra Robrecht
- , Amaro N. Taylor-Weiner
- , Johannes Bloehdorn
- , Annika Scheffold
- , Daniel Mertens
- , Sebastian Böttcher
- , Michael Kneba
- , Ulrich Jäger
- , Thorsten Zenz
- , Michael K. Wenger
- , Guenter Fingerle-Rowson
- , Clemens Wendtner
- , Anna-Maria Fink
- , Catherine J. Wu
- , Barbara Eichhorst
- , Kirsten Fischer
- , Michael Hallek
- , Hartmut Döhner
- & Stephan Stilgenbauer
-
Research | | Open
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
- Stephan.Stilgenbauer@uniklinik-ulm.de
-
Reviews |
From pathogenesis to treatment of chronic lymphocytic leukaemia
- stephan.stilgenbauer@uniklinik-ulm.de
-
Research | | Open
-
Research |
Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL)
- stephan.stilgenbauer@medizin.uni-ulm.de
-
Correspondence |
How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance
- stephan.stilgenbauer@uniklinik-ulm.de
